<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <id>https://macwaneric.github.io/cancer.rss.feed/index.html</id>
    <title>CancerFeed</title>
    <updated>2023-06-09T01:08:37.522Z</updated>
    <generator>osmosfeed 1.15.1</generator>
    <link rel="alternate" href="https://macwaneric.github.io/cancer.rss.feed/index.html"/>
    <link rel="self" href="https://macwaneric.github.io/cancer.rss.feed/feed.atom"/>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[New approaches to idiopathic neutropenia in the era of clonal hematopoiesis]]></title>
        <id>pubmed:37118760</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...]]></summary>
        <author>
            <name>Olisaemeka D Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The burden of rare protein-truncating genetic variants on human lifespan]]></title>
        <id>pubmed:37117740</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...]]></summary>
        <author>
            <name>Jimmy Z Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Young Women Treated for Breast Cancer]]></title>
        <id>pubmed:37115512</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.]]></summary>
        <author>
            <name>Christopher J Gibson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single duplex DNA sequencing with CODEC detects mutations with high sensitivity]]></title>
        <id>pubmed:37106072</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules ('single duplexes') to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...]]></summary>
        <author>
            <name>Jin H Bae</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions]]></title>
        <id>pubmed:37105856</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...]]></summary>
        <author>
            <name>Kennedy K Howland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing]]></title>
        <id>pubmed:37105769</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A tumor's heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell's mutation and identify...]]></summary>
        <author>
            <name>Ya-Hong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells]]></title>
        <id>pubmed:37100116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...]]></summary>
        <author>
            <name>Michael D Milsom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers]]></title>
        <id>pubmed:37090647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...]]></summary>
        <author>
            <name>Adam C Weiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers]]></title>
        <id>pubmed:37092904</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...]]></summary>
        <author>
            <name>Michael S Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study]]></title>
        <id>pubmed:37088956</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.]]></summary>
        <author>
            <name>Laura Boucai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor Murine Double Minute X (MDMX) plays crucial roles especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor Murine Double Minute X (MDMX) plays crucial roles especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor Murine Double Minute X (MDMX) plays crucial roles especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum of clonal hematopoiesis in VEXAS syndrome]]></title>
        <id>pubmed:37084382</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...]]></summary>
        <author>
            <name>Fernanda Gutierrez-Rodrigues</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation]]></title>
        <id>pubmed:37084069</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet's disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...]]></summary>
        <author>
            <name>Yuki Sato</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <em>TET2</em>, <em>TP53</em>, and <em>CBL</em> mutations]]></title>
        <id>pubmed:37083525</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....]]></summary>
        <author>
            <name>Ahmed A Z Dawoud</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing]]></title>
        <id>pubmed:37079859</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.]]></summary>
        <author>
            <name>Michael J Slade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor Murine Double Minute X (MDMX) plays crucial roles especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies]]></title>
        <id>pubmed:37086813</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor Murine Double Minute X (MDMX) plays crucial roles especially in leukemia initiation. MDMX is broadly...]]></summary>
        <author>
            <name>Koki Ueda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA]]></title>
        <id>pubmed:37081523</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.]]></summary>
        <author>
            <name>Ariana Huebner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort]]></title>
        <id>pubmed:37079068</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...]]></summary>
        <author>
            <name>Daniele Cattaneo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Obesity induced inflammation exacerbates clonal hematopoiesis]]></title>
        <id>pubmed:37071471</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...]]></summary>
        <author>
            <name>Santhosh Kumar Pasupuleti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy]]></title>
        <id>pubmed:37072406</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...]]></summary>
        <author>
            <name>Qi Xu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bladder cancer organoids as a functional system to model different disease stages and therapy response]]></title>
        <id>pubmed:37072390</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...]]></summary>
        <author>
            <name>Martina Minoli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time]]></title>
        <id>pubmed:37066022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...]]></summary>
        <author>
            <name>Sanjana Rajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment]]></title>
        <id>pubmed:37061644</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...]]></summary>
        <author>
            <name>Qiu-Luo Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Origins and determinants of evolution]]></title>
        <id>pubmed:37075557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...]]></summary>
        <author>
            <name>Lourdes M Mendez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review]]></title>
        <id>pubmed:37057121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...]]></summary>
        <author>
            <name>Bartłomiej Tomasik</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms]]></title>
        <id>pubmed:37052531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230413205532&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...]]></summary>
        <author>
            <name>Juan Carlos Balandrán</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230428205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer]]></title>
        <id>pubmed:37086716</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...]]></summary>
        <author>
            <name>Clare E Weeden</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model]]></title>
        <id>pubmed:37047167</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the 'atavistic reversal', 'cancer attractor', 'somatic mutation', 'genome chaos', and 'tissue organization field' theories. The 'atavistic reversal' theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called 'gradual atavism', and evidence for the 'serial atavism' model. We showed the gradual core-to-periphery evolutionary growth of the human...]]></summary>
        <author>
            <name>Alexander E Vinogradov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37052539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230413205530&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.]]></summary>
        <author>
            <name>Magdalena Czader</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma]]></title>
        <id>pubmed:37046647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230413205530&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...]]></summary>
        <author>
            <name>Matteo Italia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal haematopoiesis and risk of chronic liver disease]]></title>
        <id>pubmed:37046084</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046084/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic liver disease is a major public health burden worldwide¹. Although different aetiologies and mechanisms of liver injury exist, progression of chronic liver disease follows a common pathway of liver inflammation, injury and fibrosis². Here we examined the association between clonal haematopoiesis of indeterminate potential (CHIP) and chronic liver disease in 214,563 individuals from 4 independent cohorts with whole-exome sequencing data (Framingham Heart Study, Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Waihay J Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis]]></title>
        <id>pubmed:37046083</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046083/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in a diverse set of driver genes increase the fitness of haematopoietic stem cells (HSCs), leading to clonal haematopoiesis¹. These lesions are precursors for blood cancers^(2-6), but the basis of their fitness advantage remains largely unknown, partly owing to a paucity of large cohorts in which the clonal expansion rate has been assessed by longitudinal sampling. Here, to circumvent this limitation, we developed a method to infer the expansion rate from data from a single time point....]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230428205526&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis]]></title>
        <id>pubmed:37045808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230413205532&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...]]></summary>
        <author>
            <name>N Zioni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230413205532&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy]]></title>
        <id>pubmed:37042724</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230412205511&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.]]></summary>
        <author>
            <name>Christina Mayerhofer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230427205816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230426205911&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230425205646&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230424205743&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230423205815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230422210150&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230421205657&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of lung cancer and impact of subclonal selection in TRACERx]]></title>
        <id>pubmed:37046096</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230413205530&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...]]></summary>
        <author>
            <name>Alexander M Frankell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The evolution of non-small cell lung cancer metastases in TRACERx]]></title>
        <id>pubmed:37046095</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230413205530&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...]]></summary>
        <author>
            <name>Maise Al Bakir</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary characterization of lung adenocarcinoma morphology in TRACERx]]></title>
        <id>pubmed:37045996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230413205530&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...]]></summary>
        <author>
            <name>Takahiro Karasaki</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230413205530&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The clonal heterogeneity of colon cancer with liver metastases]]></title>
        <id>pubmed:37042990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230412205510&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.]]></summary>
        <author>
            <name>Guanxuan Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[clevRvis: visualization techniques for clonal evolution]]></title>
        <id>pubmed:37039116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230420205609&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.]]></summary>
        <author>
            <name>Sarah Sandmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[clevRvis: visualization techniques for clonal evolution]]></title>
        <id>pubmed:37039116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230419205601&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.]]></summary>
        <author>
            <name>Sarah Sandmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[clevRvis: visualization techniques for clonal evolution]]></title>
        <id>pubmed:37039116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230418205831&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.]]></summary>
        <author>
            <name>Sarah Sandmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[clevRvis: visualization techniques for clonal evolution]]></title>
        <id>pubmed:37039116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230417205516&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.]]></summary>
        <author>
            <name>Sarah Sandmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[clevRvis: visualization techniques for clonal evolution]]></title>
        <id>pubmed:37039116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230416205720&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.]]></summary>
        <author>
            <name>Sarah Sandmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[clevRvis: visualization techniques for clonal evolution]]></title>
        <id>pubmed:37039116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230415205856&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.]]></summary>
        <author>
            <name>Sarah Sandmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[clevRvis: visualization techniques for clonal evolution]]></title>
        <id>pubmed:37039116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230414205813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.]]></summary>
        <author>
            <name>Sarah Sandmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[clevRvis: visualization techniques for clonal evolution]]></title>
        <id>pubmed:37039116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230413205530&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.]]></summary>
        <author>
            <name>Sarah Sandmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[clevRvis: visualization techniques for clonal evolution]]></title>
        <id>pubmed:37039116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230412205510&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.]]></summary>
        <author>
            <name>Sarah Sandmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[clevRvis: visualization techniques for clonal evolution]]></title>
        <id>pubmed:37039116</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230411205624&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.]]></summary>
        <author>
            <name>Sarah Sandmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nodal interferon exposure drives tumour-specific tolerance]]></title>
        <id>72a3a11d39c217b1a80cbb551444e6f6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1533878403463405569"/>
        <updated>2022-06-06T18:28:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nodal interferon exposure drives tumour-specific tolerance https://t.co/FT4NeBcFTg pic.twitter.com/NRHkVDUsOr
— NatureReviewsCancer (@NatureRevCancer) June 6, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VIBConferences: #Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.⏰Registration Deadline: Thursday 2 June. Read more]]></title>
        <id>bb6bc242bcbc356c4a38db850e74d812</id>
        <link href="https://twitter.com/VIBConferences/status/1531132720952266752"/>
        <updated>2022-05-30T04:37:42.000Z</updated>
        <summary type="html"><![CDATA[#Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.
⏰Registration Deadline: Thursday 2 June. Read more https://t.co/cc0HC5cj6W pic.twitter.com/u8LFuzBbsV
— VIB Conferences (@VIBConferences) May 30, 2022]]></summary>
        <author>
            <name>@VIBConferences</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy]]></title>
        <id>ed6c996dc1a718afb523de6229a53131</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530198403686072320"/>
        <updated>2022-05-27T14:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy https://t.co/wjuHplkpof pic.twitter.com/1SoKYhRsPO
— NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 👇🏻💌]]></title>
        <id>d15a3a4b24853812d7fa21fd56de5815</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530174481313972224"/>
        <updated>2022-05-27T13:10:00.000Z</updated>
        <summary type="html"><![CDATA[Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 👇🏻
💌 https://t.co/Fo6XRWV3OZ@natrescancer pic.twitter.com/rbxRPqLV6g
— NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@UlrikeHarjes: This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer:  do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest☺️]]></title>
        <id>fe13755a2693ea65459e5e21df097d2a</id>
        <link href="https://twitter.com/UlrikeHarjes/status/1529747629936193537"/>
        <updated>2022-05-26T08:53:50.000Z</updated>
        <summary type="html"><![CDATA[This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer: https://t.co/p3Y2cdNhco
I do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest☺️ https://t.co/qWH2dTv8j9
— Ulrike Harjes (@UlrikeHarjes) May 26, 2022]]></summary>
        <author>
            <name>@UlrikeHarjes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Developing dietary interventions as therapy for cancer]]></title>
        <id>9ba5279424b31b0122a4ae20c18e6d03</id>
        <link href="https://twitter.com/NatureRevCancer/status/1529516411059437568"/>
        <updated>2022-05-25T17:35:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Developing dietary interventions as therapy for cancer https://t.co/ijuqctk1wJ pic.twitter.com/KHPpMKnCFa
— NatureReviewsCancer (@NatureRevCancer) May 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Digging for treasures in the tumour interactome]]></title>
        <id>611d40f2e6ea2796b028bebda41a86dd</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526928478490095616"/>
        <updated>2022-05-18T14:11:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Digging for treasures in the tumour interactome https://t.co/NhHYAwUgLE
— NatureReviewsCancer (@NatureRevCancer) May 18, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: As part of our overall commitment to diversity, equity and inclusion at Springer Nature, we’d like to better understand what DEI means within the global research community. Take the survey here]]></title>
        <id>9590a971b00448cd312078183965b21d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526560254091313156"/>
        <updated>2022-05-17T13:48:21.000Z</updated>
        <summary type="html"><![CDATA[As part of our overall commitment to diversity, equity and inclusion at Springer Nature, we’d like to better understand what DEI means within the global research community. Take the survey here https://t.co/03yLiUxFTq
— NatureReviewsCancer (@NatureRevCancer) May 17, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT 🧰 🛠️ where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial 👇🏻]]></title>
        <id>aa38ff4245b93e964773f191844ddc7a</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524772831904509953"/>
        <updated>2022-05-12T15:25:46.000Z</updated>
        <summary type="html"><![CDATA[Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT 🧰 🛠️ where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial 👇🏻 https://t.co/VbyoUJmTRJ
— NatureReviewsCancer (@NatureRevCancer) May 12, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tools for the next generation]]></title>
        <id>65aca76b9f794aaa668d84ad32dca4a0</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524068259712036864"/>
        <updated>2022-05-10T16:46:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tools for the next generation https://t.co/lEzTPFYDf5
— NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon]]></title>
        <id>afa9b6784b4ccc7c05ed4efd26ddfb2d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524022709386190856"/>
        <updated>2022-05-10T13:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon https://t.co/XXT0c9SAYX
— NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VarunVenkatara2: Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter]]></title>
        <id>43e2d5ccebc9030f737d656f47ac9d98</id>
        <link href="https://twitter.com/VarunVenkatara2/status/1520050291986604033"/>
        <updated>2022-04-29T14:40:05.000Z</updated>
        <summary type="html"><![CDATA[Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter https://t.co/S55cKTGNFd
— Varun Venkataramani (@VarunVenkatara2) April 29, 2022]]></summary>
        <author>
            <name>@VarunVenkatara2</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! An inhospitable site]]></title>
        <id>9f6b8644378881f4c2e6b6833c93fc2f</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020349068316673"/>
        <updated>2022-04-29T12:41:06.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! An inhospitable site https://t.co/0dvqIKCWxh pic.twitter.com/PtY8J9Fz7r
— NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Disconnecting multicellular networks in brain tumours]]></title>
        <id>f6d91efcd60dae769e2722585bdfa8df</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020340201598978"/>
        <updated>2022-04-29T12:41:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Disconnecting multicellular networks in brain tumours https://t.co/LJrzy8bRma pic.twitter.com/CO7BnooP0r
— NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.💌]]></title>
        <id>76e3b436bc8e43ad21366a80c120e395</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519678964364623872"/>
        <updated>2022-04-28T14:04:34.000Z</updated>
        <summary type="html"><![CDATA[Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.
💌 https://t.co/vQwHFJhpwv@natrescancer pic.twitter.com/6kYgjRYhdT
— NatureReviewsCancer (@NatureRevCancer) April 28, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@tmurraystewart: Our latest publication on #polyamines is online!@HopkinsMedicine]]></title>
        <id>fdf224ea293cdf039086d16e5699a59a</id>
        <link href="https://twitter.com/tmurraystewart/status/1519413460978704384"/>
        <updated>2022-04-27T20:29:33.000Z</updated>
        <summary type="html"><![CDATA[Our latest publication on #polyamines is online!@HopkinsMedicine https://t.co/ehRGgN1w9R
— Tracy Murray Stewart (@tmurraystewart) April 27, 2022]]></summary>
        <author>
            <name>@tmurraystewart</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity]]></title>
        <id>4f43226ec4dc8e531ff6e64a9c5ab8e6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519381375874265088"/>
        <updated>2022-04-27T18:22:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity https://t.co/YCJX1hRQLO pic.twitter.com/zRUCRNXyxH
— NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.📯]]></title>
        <id>a44ed79b9f76aad377b9272fb392f553</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519317944995569664"/>
        <updated>2022-04-27T14:10:00.000Z</updated>
        <summary type="html"><![CDATA[NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.
📯 https://t.co/JTUhX0DHQ1@natrescancer pic.twitter.com/2PdCmsDu2p
— NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino  @natrescancer @Columbia]]></title>
        <id>06ff7641d8f5fcc0dff91f835ac3bbc1</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518967636561956865"/>
        <updated>2022-04-26T14:58:00.000Z</updated>
        <summary type="html"><![CDATA[In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino
 https://t.co/GeTVCMJQsp @natrescancer
 @Columbia pic.twitter.com/ZXW6A0Fe0c
— NatureReviewsCancer (@NatureRevCancer) April 26, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tracking dormant disseminated tumour cells]]></title>
        <id>96b2ddff4eb269cf343213c6a1b1ce95</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518563607440621569"/>
        <updated>2022-04-25T12:12:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tracking dormant disseminated tumour cells https://t.co/kSXyWAvCxF
— NatureReviewsCancer (@NatureRevCancer) April 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
</feed>